Skip to main content
Premium Trial:

Request an Annual Quote

Personal Genome Diagnostics Gets CE Mark for Elio Tissue Complete Assay

NEW YORK – Personal Genome Diagnostics said today that it has successfully CE marked its PGDx Elio tissue complete assay, allowing the company to provide greater access to precision medicine for cancer patients in the European Union.

The 507-gene, next-generation sequencing panel detects single-nucleotide variants, small insertions and deletions, amplifications, rearrangements, microsatellite instability, and tumor mutational burden in DNA patient tissue samples. The assay is intended to help oncologists guide therapy selection for cancer patients across the spectrum of tumor types.

"With this assay, physicians throughout Europe will be able to secure specific, actionable information that can help them make improved treatment decisions," PGDx CEO Doug Ward said in a statement.

The newly CE-marked tissue assay joins PGDx's liquid biopsy test, called Elio Plasma Resolve, which garnered its own CE mark in March.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.